KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
KPWHRI receives $10 million to continue vaccine effectiveness research for flu, COVID-19, and other respiratory diseases
Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.
IDCRC study finds rapid decline in vaccine-boosted neutralizing antibodies against Omicron variant BA.5
New data should increase confidence in vaccine safety among people who are pregnant and more at risk for COVID-19 complications.
Participant in KPWHRI trial receives world’s first-ever injection of investigational SchistoShield vaccination.
Study includes multiple variant vaccines.
Land Acknowledgment
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.